XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenues:    
Revenue from collaborative arrangements and other contracts $ 114,943 $ 199,074
Operating expenses:    
Research and development 30,176,511 55,978,611
General and administrative 13,890,610 15,953,458
Total operating expenses 44,067,121 71,932,069
Loss from operations (43,952,178) (71,732,995)
Other income (expense):    
Interest income 2,207,171 669,814
Interest expense (313,488) (313,488)
Gain (loss) on investment in affiliated entity 616,639 (537,728)
Net unrealized gain (loss) on available-for-sale equity securities 3,218,215 (4,840,641)
Other expense, net (2,425,676) (153,468)
Net loss before share in net loss of Geneos (40,649,317) (76,908,506)
Share in net loss of Geneos 0 (2,165,213)
Net loss $ (40,649,317) $ (79,073,719)
Net loss per share    
Basic (in dollars per share) $ (0.16) $ (0.36)
Diluted (in dollars per share) $ (0.16) $ (0.36)
Weighted average number of common shares outstanding    
Basic (in shares) 258,437,714 218,940,693
Diluted (in shares) 258,437,714 218,940,693